2019 Bioelectronic Medicine Forum

April 4, 2019

Millennium Broadway, Times Square New York

Keynote Speaker

Sue Siegel, Chief Innovation Officer, GE and CEO, Business Innovations

Sue Siegel is GE’s Chief Innovation Officer and CEO of Business Innovations, leading the development and acceleration of innovation across the company. An innovator at heart, she is a seasoned executive focused on uncovering new and unconventional paths to growth. She has 30+ years of corporate, entrepreneurial, and venture capital experience, all geared at one thing: turning untapped potential into real value. In this role, Sue leads Business Innovations, a multimodal innovation engine focused on accelerating promising start-ups in GE Ventures, creating and launching new companies, licensing GE’s intellectual property, developing new markets, and nurturing innovative ideas into scalable initiatives both inside and outside of GE. To date, Sue and her team have led the creation and launch of seven new companies including Drawbridge Health, Avitas Systems, Vineti and Evidation Health, funded and accelerated growth for 100+ companies and led the creation of a novel licensing model for GE’s library of patents – connecting technology and ideas to create new avenues to growth. Previously, as a Silicon Valley-based venture capitalist at MDV, Sue led investments and served as board member for companies in personalized medicine, digital health, and life sciences. Prior to that, Sue served as president and board member of Affymetrix, where she led the company’s transformation from a pre-revenue startup to a global, multi-billion dollar market cap genomics leader. She also led strategy, technology development, licensing, manufacturing, and new market creation and development at leading organizations including Bio-Rad, DuPont, and Amersham. Sue has been recognized in Fortune as one of “34 Leaders Who Are Changing Health Care” and as one of “The 100 Most Influential Women in Silicon Valley” by Silicon Valley Business Journal. She is an Aspen Institute Crown Fellow and was featured as a “Multiplier” in the bestselling book: Multipliers: How the Best Leaders Make Everyone Smarter. Sue holds an M.S. from Boston University School of Medicine and a B.S. from the University of Puerto Rico. She lives in Silicon Valley with her husband and has two sons. She is an avid hiker and loves to spend time on the scenic trails of Northern California.

Conference Moderators

James Cavuoto, Editor and Publisher, Neurotech Reports

James Cavuoto is editor and publisher of Neurotech Business Report and the founder of Neurotech Reports. He is the lead author of "The Market for Neurotechnology," a market research report published by Neurotech Reports. Cavuoto was the founder of Micro Publishing Press, Inc., a publishing company that helped pioneer the market for electronic publishing, digital imaging, and computer graphics. He holds a degree in biomedical engineering from Case Western Reserve University, where he studied under pioneers in the field of functional electrical stimulation. He has also studied human factors engineering at University of Southern California in Los Angeles. Cavuoto spent three years as a member of the technical staff at Hughes Aircraft Company in Los Angeles, where he worked on simulation, training, and publication products produced for the U.S. Department of Defense. Cavuoto was an adjunct professor at Rochester Institute of Technology and the author of eight books on computer graphics, electronic publishing, and digital imaging. He is a member of the IEEE Engineering in Medicine and Biology Society. He has authored a chapter in the textbook Neuromodulation (Elsevier, 2009), as well as articles in Neuromodulation, Journal of Neural Engineering, Medical Device Daily, IEEE Spectrum, MX magazine, and the International Journal of Medical Marketing. He is coauthor, with Jennifer French, of Bionic Pioneers: Brave Neurotech Users Blaze the Trail to New Therapies (Neurotech Press, 2014).

Imran Eba, Partner, Action Potential Venture Capital

Imran is a partner at Action Potential Venture Capital in Cambridge, MA and invests in companies that are pioneering bioelectronic medicines and technologies. He represents Action Potential as a Board Member or Observer on the boards of Axon Therapies and SetPoint Medical. Before joining Action Potential, Imran was in the Worldwide Business Development group of GlaxoSmithKline working in a variety of business development and investing roles. Most recently, Imran led the establishment of and headed up the Investment Management practice at GlaxoSmithKline. The group was tasked with accessing technology and innovation external to GSK by making and managing investments in life science venture capital funds as limited partners and direct investments in biotechs made as part of GSK’s R&D collaborations. During his tenure the group led GSK’s commitments in excess of $200 million in a number of venture capital groups as well as participated in a number of biotech IPOs. Imran received his bachelor’s degree in finance from Concordia University in Montreal and has trained as a Canadian Chartered Accountant.

Jennifer French, Senior Editor and Associate Publisher, Neurotech Reports

Jennifer French is senior editor and associate publisher of Neurotech Reports. She is the founder of Neurotech Network, a nonprofit organization founded in Florida in 2003. Jennifer acquired her C6-7 incomplete spinal cord injury in 1998. Prior to her injury, she was recreationally active with such sports as canoeing, snowboarding/skiing, sailing, fly fishing, biking. After her injury, she still participates in all those activities. She is an active user of an FES system. Now residing in Tampa, FL, Jen is active in the community accessible sailing program, Sailing Alternatives as well as the national US Sailing, Sailors with Special Needs. French has helped launch successful divisions is such organizations as Bombardier Capital and PC Connection, Inc. With an MBA specializing in marketing & strategy, she works with for-profit and not-for-profit organizations, large and small, emerge into new markets, profile target customers and create and build systems to support sales efforts. She is the author of On My Feet Again (Neurotech Press, 2013), her personal story of rehabilitation using neurotechnology.

Jeremy Koff, Senior Contributing Editor, Neurotech Reports

Mr. Koff is senior contributing editor for Neurotech Reports and president of Colibri Partners Inc., a strategic and marketing consulting firm with a primary focus in the medical device sector. The company offers services related to market and risk analysis, clinical and technology assessments, business plan development, business/financial modeling, and market research. Mr. Koff has nearly 20 years of global experience in the medical device industry with companies including Advanced Bionics Corp., Boston Scientific, MiniMed Inc., Bioness Inc, and many others. His business plans have attracted tens of millions in start-up capital. Mr. Koff holds a Bachelor's degree in biology from Middlebury College, a Masters of Public Affairs from Indiana University, and an MBA from UCLA. He is an active classically-trained musician, supporter of the arts, and is a board member of the Fender Music Foundation.

Panelists and Presenters

Kip Ludwig, Associate Professor, University of Wisconsin-Madison

Dr. Ludwig leads the Bioelectronic Medicines Laboratory at the University of Wisconsin. The primary focus of his lab is developing next-generation neuromodulation therapies that use minimally invasive strategies to ‘wiretap’ the nervous system to treat circuit dysfunction and deliver biomolecules to target areas with unprecedented precision. Prior to Wisconsin Dr. Ludwig served as the Program Director for Neural Engineering at the National Institutes of Health. He co-led the Translational Devices Program at NINDS, led the NIH BRAIN Initiative programs to catalyze implantable academic and clinical devices to stimulate and/or record from the central nervous system, and led a trans-NIH planning team in developing the ~250 million dollar S.P.A.R.C. Program to stimulate advances in neuromodulation therapies for organ systems. Dr. Ludwig also worked in industry as a research scientist, where his team conceived, developed and demonstrated the chronic efficacy of a next-generation neural stimulation electrode for reducing blood pressure in both pre-clinical studies and clinical trials. Through his industry work he oversaw Good Laboratory Practice and non-GLP studies enabling clinical trials in Europe and the U.S., as well as participated in the protocol development and execution of those trials, leading to approval for sale in seven countries and a U.S. pivotal trial.

Victor Pikov, CEO, Medipace, Inc.

Victor Pikov is a CEO of a recently established Pasadena-based company, MediPace Inc., which is focused on the development of implantable stimulation-based therapies for the GI tract. Prior to that, for the past three years he worked at Galvani Bioelectronics and GSK Bioelectronics division, where he oversaw the development and validation of implantable pulse generators and stimulation leads (nerve cuffs and percutaneous electrodes) for several clinical applications. Prior to Galvani Bioelectronics, while at the Huntington Medical Research Institutes (2002-2015), Victor evaluated PNS and CNS neural interfaces in various models of chronic diseases, such as infertility, bladder paralysis, bladder spasticity/hyperreflexia, hearing and vision loss, tinnitus, obstructive sleep apnea, and obesity. His Ph.D. work at Georgetown University (1995-2000) was on the spinal control of bladder voiding and postdoctoral work at the California Institute of Technology (2000-2002) was on optogenetic viral vectors for neuronal stimulation. Victor holds several patent applications for noninvasive glucose measurement in the skin, neuromodulation for polycystic ovarian syndrome, and a microfluidic nerve cuff interface.

Elliot Krames, M.D., Past President, International Neuromodulation Society

Elliot Krames is a nationally and internationally known “thought leader” in the field of pain medicine and neuromodulation. He graduated from medical school at the University of Maryland and completed his residency in anesthesiology and his fellowship in obstetrical anesthesia at the University of California, San Francisco. Dr. Krames is board certified in anesthesiology and sub-certified in pain management through the American Board of Anesthesiology. He is certified in pain medicine through the American Board of Pain Medicine. The first cancer pain clinic at Mount Zion Hospital was established by Dr. Krames in 1982. He established the Pacific Pain Treatment Center in 1987. Dr. Krames was previously president of the International Neuromodulation Society and has served on the Boards of The North American Neuromodulation Society, The National Pain Foundation, The World Institute of Pain, The American Academy of Pain Medicine, and The American Board of Pain Medicine. Dr. Krames was Editor-in-Chief for 13 years of Neuromodulation, Journal of the International Neuromodulation Society. Dr. Krames has co-authored two previous books and was editor of a two volume textbook, Neuromodulation.

Marom Bikson, Ph.D., Professor of Biomedical Engineering, City College of New York

Marom Bikson, is a Cattell Professor of Biomedical Engineering at The City College of New York of the City University of New York and co-Director of the Neural Engineering Group at the New York Center for Biomedical Engineering. The translational R&D activity of his group spans pre-clinical studies, computational models, device design and fabrication, regulatory activities, and clinical trials. Technologies developed by his group are in clinical trials in over 100 medical centers and include neuromodulation interventions for neuropsychiatric disorders, intra- and post-operative sensors, patient compliance tools, and surgeon training simulators. Dr. Bikson has published over 200 papers and book chapters and is inventor on over 30 patent applications. He is known for his work on brain targeting with electrical stimulation, cellular physiology of electric effects, and electrical safety. Dr. Bikson co-invented High-Definition transcranial Direct Current Stimulation, the first noninvasive, targeted, and low-intensity neuromodulation technology. Dr. Bikson consults for medical technology companies and regulatory agencies on the design, validation, and certification of medical instrumentation. Prior to becoming faculty at CUNY, Dr. Bikson was a research fellow at the University of Birmingham Medical School, U.K. and a Research Associate at Sontra Medical LLC, in Cambridge, Massachuesetts. Dr. Bikson received his Ph.D. in Biomedical Engineering from Case Western Reserve University, in Cleveland, OH and a B.S. in Biomedical Engineering from Johns Hopkins University, Baltimore, MD.

Entrepreneur Presenters

Thomas Oxley, M.D., Ph.D., CEO, Synchron Inc.

Dr. Oxley is the founder and CEO of Synchron, and led the original team that created the Stentrode device at the University of Melbourne. He now leads the company and also holds the position of neurointerventionalist in the department of neurosurgery at Mount Sinai Health System, after having completed an endovascular neurosurgery fellowship at Mount Sinai Hospital under Dr. J Mocco and Dr. Alejandro Berenstein. Dr. Oxley also completed residencies in both internal medicine and neurology, as well as a stroke fellowship, and holds a Ph.D. from the University of Melbourne in neural engineering, which includes advanced MRI imaging analysis, hardware device (stent) development, and electrophysiological signal processing. His work has been published in major journals including Nature Biotechnologyand New England Journal of Medicine. Dr. Oxley established the Vascular Bionics laboratory at the University of Melbourne, which received substantial funding from DARPA, and is the founder of three start-up companies: SmartStent, VascuLab, and Synchron.

Don Deyo, CEO, FemPulse LLC

Don Deyo is the CEO of FemPulse LLC. Prior to this, Mr. Deyo served in executive leadership roles at Medtronic, Inc., the world’s largest medical device company. He also founded the executive consultancy MedTech Execs, which provides strategic and operational services to medical device and pharmaceutical companies through a global network of experienced executives. While with Medtronic, Mr. Deyo was Vice President of Research & Development for Neuromodulation, Vice President of Product Development & Technology for Cardiac Rhythm Management and Vice President and General Manager for Medtronic Paceart. Mr. Deyo holds advanced degrees in engineering and business administration.

Jennifer Ernst, Co-founder and CEO, Tivic Health Systems Inc.

Jennifer Ernst is CEO at Tivic Health Systems Inc. in Menlo Park, CA. Her career in technology has been characterized by driving transformational technology to market. She began her career at Xerox PARC in Palo Alto, one of the world’s leading research laboratories, focused on getting technology out of the lab and into the market. She held varying roles in strategic business development, marketing, and sales. Ernst holds an MBA from Santa Clara University, graduating with honors. For the past 15 years, Ernst has dedicated herself to identifying and building global businesses out of cutting-edge technologies. Prior to founding Tivic Health, she served as executive vice president of sales and marketing, chief strategy officer, and CEO of the U.S. subsidiary of Thin Film Electronics. Of note, she launched early electronic labels which led to the company winning the Wall Street Innovation Award and the World Technology Award. In addition, as part of the company’s executive management, Ernst transformed the company from an eight-person R&D company to a recognized leader in printed electronics with a peak market cap of $480 million in less than five years.

Daniel Powell, CEO, Spark Biomedical Inc.

Daniel Powell has more than 20 years experience developing and selling technology-based products and has served in leadership roles in upstream and downstream marketing, business development, strategic planning, and program management. Powell launched more than 18 medical device products during his career at St. Jude Medical (now Abbott) and Cyberonics (now LivaNova). He has a wide range of experience in the the neurological disorders space including movement disorders, psychiatric disorders, and epilepsy. Additionally, Powell has in-depth experience in interventional neuromodulation technology, both implanted and external, as well as other active implantable medical technology, bio monitoring, and disease management systems. Powell now leads his own startup, Spark Biomedical, and acts as an advisor for other startups in the industry.

Bill Edelman, CEO and Chairman, Highland Instruments, Inc.

Bill Edelman is a medical device industry executive with more than 32 years experience and currently serves as the CEO of Highland Instruments. Mr. Edelman was most recently president & CEO, TYRX, Inc., a commercial stage venture-backed medical device company focused on drug/device implant products for general surgery, electrophysiology, and cosmetic surgery. Prior to TYRX, Mr. Edelman has held executive level positions at MicroSense International, LLC (bio-sensing), FibraSonics, Inc. (ultrasonic surgical products), NeuroMod, Inc. (neurostimulation technologies), St. Jude Medical, Inc., Pfizer, Inc., and Baxter International, Inc.

Gaurav Sharma, Technical Leader in Neuromodulation, Battelle

Gaurav Sharma’s work has helped a paralyzed patient regain control of his hand and enabled delivery of drugs across the blood-brain barrier. As the Lead Investigator and Senior Research Scientist on the Battelle Medical Devices and Neuromodulation team, he is applying advanced engineering to overcome problems in the human body and brain. Since joining Battelle in 2011, Gaurav has served as the technical lead or lead investigator on a number of cutting-edge projects involving peripheral nerve stimulation, spinal cord stimulation, and brain-computer interfaces. He was also the lead investigator for the Blood-Brain Barrier engineering program, a Defense Threat Reduction Agency-funded project aimed at developing nanotechnology-based strategies for delivery of drugs to the brain. Gaurav’s work is informed by his background in biomedical and mechanical engineering. He holds a Ph.D. in mechanical engineering from Northeastern University, an M.S. in mechanical and aerospace engineering from Rutgers University and a B.S. in mechanical engineering from the National Institute of Technology in Surathkal, India. His doctoral work was focused on the development of protein-based bio-nano sensors. In his postdoctoral work at the Sanford-Burnham Medical Research Institute, he expanded on this work to develop nanotechnology-based strategies for engineering the tumor microenvironment as a therapeutic strategy against breast cancer. His background in engineering, advanced materials, and biology has given him a cross-disciplinary perspective that has been invaluable in solving difficult challenges in medical device design.

site design by shalatdesign | shalat.com